Developmental toxicity study of sodium molybdate dihydrate administered in the diet to Sprague Dawley rats  by Jay Murray, F. et al.
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Molybdenum  is an essential  nutrient  for humans  and  animals  and is  a constituent  of  several  important
oxidase  enzymes.  It  is normally  absorbed  from  the diet  and to a lesser  extent  from  drinking  water  and
the  typical  human  intake  is around  2 g/kg bodyweight  per day.  No  developmental  toxicity  studies  to
contemporary  standards  have  been  published  and  regulatory  decisions  have  been  based  primarily  on
older studies  where  the  nature  of  the  test  material,  or the  actual  dose  levels  consumed  is uncertain.
In the  current  study  the  developmental  toxicity  of  sodium  molybdate  dihydrate  as a  representative
of  a  broad  class  of soluble  molybdenum(VI)  compounds,  was  given  in  the  diet  to  Sprague  Dawley  ratsolybdate
iet
evelopmental
oxicity
etus
in  accordance  with  OECD  Test  Guideline  414.  Dose  levels  of 0, 3, 10,  20 and  40  mg  Mo/kg  bw/day  were
administered  from  GD6  to  GD20.  No  adverse  effects  were  observed  at any  dose  level  on  the  dams,  or  on
embryofetal  survival,  fetal  bodyweight,  or development,  with  no increase  in  malformations  or  variations.
Signiﬁcant  increases  in  serum  and  tissue  copper  levels  were  observed  but  no  toxicity  related  to  these  was
observed.  The  NOAEL  observed  in this  study  was  40  mg  Mo/kg  bw/day,  the  highest  dose  tested.
ublisopper
ats
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. Introduction
Molybdenum (Mo) is an essential nutrient for humans, as well as
or animals and plants [1]. In humans and other mammals, molyb-
enum is a key component of several important enzymes, including
ldehyde oxidase, sulﬁte oxidase, and xanthine oxidase [2]. Human
xposure to molybdenum may  occur via the diet, drinking water, or
nhalation from occupational exposure from mining operations and
arious industrial uses. The USA National Research Council (NRC)
as published a Recommended Dietary Allowance (RDA) of molyb-
enum for adult men  and women of 45 g/day. The average dietary
ntake of molybdenum by adult men  and women is stated to be 109
nd 76 g/day, respectively, and a Tolerable Upper Intake Level (UL)
s set at 2 mg/day [1]. In a review of intakes in the USA and Europe,
n average adult human intake of molybdenum of about 2 g/kg
odyweight per day has been reported [3], corresponding to about
40 g/day for a 70 kg person.
∗ Corresponding author. Tel.: +44 07812 414014.
E-mail addresses: jmurray2@sbcglobal.net (F. Jay Murray), rwt@rti.org (R.W. Tyl),
sullivan@mistral.co.uk (F.M. Sullivan), Asheesh.Tiwary@chevron.com (A.K. Tiwary),
seimoa@gmail.com, sandracarey@imoa.info (S. Carey).
ttp://dx.doi.org/10.1016/j.reprotox.2014.09.001
890-6238/© 2014 The Authors. Published by Elsevier Inc. This is an open access article unhed  by  Elsevier  Inc.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
In humans, the toxicity of molybdenum compounds has been
observed to be relatively low. In general, soluble molybdenum(VI)
compounds (e.g., sodium molybdate dihydrate) are more toxic
than insoluble molybdenum compounds [4]. Dietary intake of high
levels of molybdenum can alter copper metabolism in humans,
resulting in an increase in copper excretion and elevated levels of
bound plasma copper [5]. The symptoms of molybdenum toxicity
in animals are similar to those of copper deﬁciency, and copper
supplementation is effectively used to reverse molybdenum toxic-
ity (and vice versa).
Published toxicity studies in rats have suggested that oral
administration of sodium molybdate dihydrate at daily dose lev-
els of 30 and 50 mg/kg bw/day of sodium molybdate can induce
testicular damage [6] and, at drinking water concentrations of
10 mg  Mo/L or greater, interferes with oestrus cycles [7]. The actual
dose levels (mg  Mo/kg/day) used by Fungwe et al. [7] study are
unclear because the authors reported only drinking water concen-
trations (0, 5, 10, 50 and 100 mg Mo/L) without data on maternal
body weights and drinking water consumption; however, by mak-
ing assumptions, Vyskocil and Viau [4] estimated the dose levels
in the Fungwe et al. [7] study were approximately 0, 0.9, 1.6, 8.3
and 16.7 mg  Mo/kg/day, respectively. These estimates, while ten-
uous, will be used throughout this article. Importantly, no effect
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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n semen quality, oestrus cycles or the histopathology of male or
emale reproductive organs was observed in a recent 90-day, OECD
est Guideline 408 compliant, toxicity study in rats fed diets con-
aining sodium molybdate dihydrate at higher dose levels up to
0 mg  Mo/kg bw/day [8].
A review of the literature revealed limited studies of the poten-
ial developmental toxicity of molybdenum compounds. Fungwe
t al. [7] reported increased resorptions and decreased fetal body
eight among the offspring of pregnant Sprague Dawley rats given
pproximately 1.6 mg  Mo/kg bw/day as sodium molybdate dihy-
rate in the drinking water from postnatal day 21 (PND 21) through
evelopment and mating to gestation day 21 (GD 21). External
xamination of the fetuses did not reveal any signiﬁcant increase in
he incidence of congenital abnormalities. Histopathological ﬁnd-
ngs of fetuses of dams given approximately 1.6 mg  Mo/kg bw/day
r greater were reported as “fetuses appeared to be at an earlier
tage of embryonic development,” i.e., a ﬁnding consistent with
educed fetal body weight. An important criticism of the study
owever, is that it is not possible to determine the exact dose
evels of molybdenum consumed by the pregnant dams as no data
n water consumption were reported. This is further reviewed in
he Section 4.
In another developmental toxicity study, pregnant Wistar rats
ere given 0, 10, 20, or 40 mg/kg bw/day of a substance described
s “molybdenum acid ammonium salts” by gavage on GD 7–16, but
he speciﬁc chemical identity, purity or source of the test mate-
ial was not provided [9]. Signiﬁcant decreases in the percentage
f live fetuses per litter, fetal bodyweight, and statistically signiﬁ-
ant increases in the incidences of external, visceral and skeletal
alformations were reported at 40 mg/kg bw/day. However the
tudy is very poorly reported, with obvious errors. For example,
t is stated that 75 pregnant rats were randomly divided into 5
roups of 15 rats with a control and 4 treatment groups. In the con-
rol group, the mean number of implanted embryos is reported as
4.11 ± 2.34, yet the total live and dead fetuses are reported as 103
nd 7 respectively, with a 93.6% rate of live fetuses, which is clearly
ncorrect since a total of over 200 implants would be expected. Sim-
lar numbers are reported in the other treated groups. It is therefore
mpossible to assess the results of this study.
Given the uncertainties of the developmental toxicity studies in
he literature, the objective of the current study was  to assess the
otential developmental toxicity of sodium molybdate dihydrate
hen given in the diet to Sprague Dawley rats in a GLP-compliant
uideline study. This study was conducted at RTI International,
SA in accordance with OECD Test Guideline 414 [10]. Sodium
olybdate dihydrate was selected as a source of the molybdate
on [MoO4]2− that would be representative of the broader class of
oluble molybdenum(VI) compounds, since at physiological pH in
iological systems, dissolved molybdenum(VI) compounds exist in
he form of molybdate ion.
. Materials and methods
.1. Test article and diet analysis
Sodium molybdate dihydrate (Na2MoO4·2H2O; SMD), white
rystals, with a purity of 99.9% was supplied by Climax Molybde-
um, Phoenix, AZ, USA. For administration to the animals in the
iet, the SMD  was formulated in Certiﬁed Purina Rodent Chow 5002
Purina Mills, Inc., Richmond, IN, USA) at RTI International at various
oncentrations using GLP-compliant procedures and equipment.
nalyses of test chemical in the dosed feed formulations were con-
ucted by Justin Zyskowski, DCPAH, at Michigan State University,
ansing, MI,  USA. Homogeneity of the dosed feed formulations was
valuated at the lowest and highest proposed dietary concentra-
ions.oxicology 49 (2014) 202–208 203
2.2. Animals and treatment
One hundred and twenty ﬁve mated Sprague Dawley rats,
(nomenclature Crl:CD(SD)), were obtained from Charles River Lab-
oratories, Raleigh, NC, at 8–10 weeks of age upon arrival on
gestational day (GD) 0 or 1. Date of detecting a positive vaginal
smear at the vendor was  designated GD 0. All animals were used
in compliance with the NRC Guide for the use of animals [11]. The
test animals were divided into 5 groups of 25 by stratiﬁed ran-
domization by body weight on GD 3, to provide uniform mean
body weights across dose groups (±20%). They were housed in the
RTI Animal Research Facility (ARF) in non-barrier rooms in solid-
bottom, polycarbonate caging, singly housed during gestation to
GD 20, with room temperature 72 ± 3 ◦F (∼22 ± 2 ◦C); RH 50 ± 20%;
light cycle 12-h light:12-h dark; and 10–15 air changes per hour.
The Purina diet and City of Durham tap water were available ad
libitum. The drinking water was analyzed monthly by the City of
Durham, NC.
2.3. Elemental analysis of serum, placentae, livers and kidneys
At the termination of the study, blood and other tissue sam-
ples were taken from 10 rats per group as described in Section
2.6.1 and analyzed for molybdenum, copper, zinc, manganese, iron,
cobalt and selenium. Collected samples were frozen in liquid nitro-
gen and shipped on dry ice to the analytical laboratory for analysis
at Michigan State University (East Lansing, MI) using a validated
inductively coupled plasma mass spectrometry (ICP-MS; Agilent
7500ce) method. The same laboratory and instrument was  also
used to analyze the feed samples.
2.4. Study design
2.4.1. Treatment groups
Timed-mated females were assigned to treatment groups by
stratiﬁed randomization by body weight as described above. This
study was  conducted with 4 treatment groups and a vehicle control
group, each comprising 25 timed-mated females.
Concentrations of sodium molybdate dihydrate (SMD) in the
diet in parts per million (ppm; mg/kg feed) were prepared, based on
measured intakes from a range-ﬁnding study [12], to provide target
molybdenum intakes of 0, 3, 10, 20 and 40 mg Mo/kg bw/day. The
corresponding sodium molybdate dihydrate concentrations in the
diet were 0, 100, 338, 675 and 1350 ppm, respectively. On GD 0 or
1 (day of arrival at RTI) to GD 5, dams received the control feed ad
libitum. From GD 6 through GD 20, the dosed feed was  presented
to the dams in feed jars, available ad libitum 7 days/week.
2.5. Maternal observations
Clinical observations (out of cage) were conducted and recorded
at least once daily. Clinical observation records included the time
the clinical signs were observed and the severity and duration of
the signs. Daily morbidity/mortality checks were done twice per
day, at least 6 h apart, beginning the day after receipt. Individual
body weights and food consumption were measured on GD 3, 6, 9,
12, 15, 18, and 20, at approximately the same time in the morning
each day.
2.6. Scheduled necropsy
2.6.1. Maternal
On GD 20 ﬁnal body weights in grams were taken and all dams
were euthanized by CO2 asphyxiation. Serum from 10 arbitrarily
selected females per group, collected via cardiac puncture, liv-
ers and kidneys (2 per female) and placentae from the same 10
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emales/group were frozen in liquid nitrogen and stored at −80 ◦C
ntil shipped to the analytical laboratory, at Michigan State Uni-
ersity, and analyzed for molybdenum, manganese, iron, cobalt,
opper, zinc and selenium concentrations.
Uterus, liver and kidney weights were recorded, ovarian corpora
utea counts performed, and maternal gross lesions were retained
n 10% formalin. Histopathological evaluation of livers and kid-
eys from the remaining 15 pregnant control females and from
5 pregnant high dose females were performed.
.6.2. Embryofetal evaluation
Uterine implantation sites were classiﬁed as live fetus, dead
etus, early resorption or late resorption. Live fetuses were diss-
cted from the uterus after maternal termination on GD 20 and
mmediately placed on a moist paper towel over a tray of ice, a pro-
edure that induces anesthesia and subsequent death by lowering
he core body temperature below 25 ◦C [13,14]. All live fetuses were
eighed and sexed and subjected to external examination. Half of
he fetuses were then evaluated by fresh visceral examination after
emoval and ﬁxation of the heads in Bouin’s ﬂuid, and all fetuses,
ntact and decapitated, were stained in Alizarin Red S (for bone)
nd Alcian Blue (for cartilage) [15]. The intact fetal skeletons (50%)
ere then evaluated.
.7. Statistical analyses
All RTI-generated data were collected on the validated RTI
nstem ProvantisTM System, and all statistical analyses were per-
ormed using ProvantisTM software. For all statistical tests, P < 0.05
as used as the criterion for signiﬁcance and the dam or lit-
er was used as the statistical unit as appropriate. Quantitative
ontinuous data (e.g., maternal body weights and weight gains,
eed consumption in g/day and g/kg body weight/day) were sub-
ected to the ProvantisTM generalized ANOVA/ANCOVA test. This
ecision tree includes analysis of variance (ANOVA) and covari-
nce (ANCOVA), nonparametric analysis of variance, pairwise tests
16,17] for parametric and nonparametric data, and Levene’s test
18] for homogeneity of variance. For each variable analyzed, where
here was evidence of differences between groups, the methodol-
gy also identiﬁed those groups, which differed from the control
roup for these variables.
The uterine weight and uterine implant data were subjected to
he Kruskal–Wallis nonparametric analysis of variance, the default
echnique in ProvantisTM [19,20]. When there was evidence of a sig-
iﬁcant group effect, pairwise comparisons of each treated group
ith the control group were performed using Dunnett’s test on the
anks. The fetal weights and sex ratios were subjected to a 1-way
ixed ANOVA, the default technique in ProvantisTM. When there
as evidence of a signiﬁcant group effect, pairwise comparisons of
ach treated group with the control group were performed using
unnett’s test on group least square means.
Statistical analyses of the Michigan State University analytical
ata on blood and tissue minerals were performed using Students
-test, 2 tailed, heteroskedastic compared with corresponding con-
rols, and P < 0.01 was used as the criterion for signiﬁcance.
. Results
.1. Chemical analyses of feed
Analyses indicated that the high and low dose formulations
ere stable for at least 28 days at room temperature and that the
ietary dose formulations of sodium molybdate dihydrate (SMD) in
he feed at 0, 100, 338, 675, and 1350 ppm (parts per million) were
ccurate; all dietary samples were well within ±10% of the tar-
et concentrations of molybdenum, and were homogeneous. Theoxicology 49 (2014) 202–208
concentrations of SMD  added to the diet of 0, 100, 338, 675, and
1350 ppm provided target molybdenum concentrations of 0, 40,
134, 268, and 536 ppm. The analyses of molybdenum in the feed
samples gave actual concentrations of molybdenum of 1.75–1.80,
39.7–40.8, 134–139, 264–268, and 540–542 ppm for the 0, 40, 134,
268, and 536 ppm feeds, respectively.
3.2. Maternal results
Of the 125 female rats in the study, only one, in the
20 mg  Mo/kg bw/day dose group, was not pregnant. None of the
females died during the study, and none of the pregnant females
aborted or had complete resorptions at scheduled necropsy. All 25
pregnant females at 0, 3, 10, and 40 mg  Mo/kg bw/day and all 24
pregnant females at 20 mg  Mo/kg bw/day had live litters at sched-
uled termination.
Mean maternal body weights during gestation were equivalent
across all groups on GD 3, 6, 9, 12, 15, 18, and 20, with no sig-
niﬁcant differences in bodyweights or bodyweight gains during
treatment. The mean (±SEM) bodyweights of the groups at start
of treatment on GD 6 ranged from 250 ± 2.53 g to 254 ± 2.61 g, and
on GD 20 ranged from 367 ± 4.75 g to 377 ± 4.65 g with no dose
related trend. The mean maternal feed consumption values in g/day
and g/kg bw/day during gestation were also equivalent across all
groups for all gestational intervals. The mean (±SEM) daily food
intakes between GD 6 and GD 20 in the control, 3, 10, 20 and
40 mg  Mo/kg bw/day groups were 21.2 ± 0.5, 22.0 ± 0.6, 22.7 ± 0.6,
22.8 ± 0.8 and 21.0 ± 0.6 g/day, respectively.
The actual mean ± SEM molybdenum intake during GD 6–20
in the nominal target dose level groups of 3, 10, 20, and
40 mg  Mo/kg bw/day was 2.8 ± 0.07; 9.8 ± 0.24; 20.0 ± 0.68; and
37.5 ± 1.0 mg  Mo/kg bw/day, respectively. The molybdenum con-
tent of the control diet was 1.8 mg  Mo/kg diet, and the drinking
water contained 0.2 g Mo/L, giving an additional intake of
0.13 mg  Mo/kg bw/day in all groups, including controls, and was
not included in the above intake values.
There were no treatment- or dose-related maternal clinical signs
in any female in any group. At scheduled necropsy on GD 20, there
were no differences across groups for mean terminal body weight,
gravid uterine weight, net body weight (terminal body weight
minus gravid uterine weight), or for corrected mean body weight
change from GD 3 to GD 20. Maternal terminal body weights, and
absolute and relative (to terminal body weight) maternal liver and
paired kidney weights were all statistically and biologically equiv-
alent across all groups.
At terminal necropsy, all maternal kidneys were subjected to
gross pathological examination from all females on study; one
female at 40 mg  Mo/kg bw/day exhibited kidney discoloration, pale,
bilateral, misshapen kidneys, bilateral, and dilation, bilateral, of the
renal pelvis, and one female at 40 mg  Mo/kg bw/day exhibited right
renal pelvis dilation (they both had live litters). All maternal livers
were also subjected to gross pathological evaluation, with no visible
(gross) lesions observed.
Histopathological evaluation of maternal livers and kidneys of
the 15 (of 25) dams per group not used for elemental analyses, indi-
cated no treatment- or dose-related incidences or severities of any
histopathological ﬁndings in the top dose group animals compared
with the controls.
3.3. Embryofetal results
The maternal ovarian and uterine implantation data, fetal num-
bers and bodyweights are shown in Table 1 and indicated no
treatment- or dose-related differences across groups for the num-
bers of ovarian corpora lutea/female, the numbers of uterine
implantations/female, for pre- or post-implantation loss, litter size
F. Jay Murray et al. / Reproductive Toxicology 49 (2014) 202–208 205
Table  1
Summary of uterine implantation data (GD20) from rats exposed to dietary sodium molybdate dihydrate (SMD) on days 6–20 of gestation (GD 6–20).
Dose group: SMD  ppm in diet (mg  Mo/kg bw/day) 0 100 338 675 1350
0  3 10 20 40
Number of females with live fetuses at scheduled termination 25 25 25 24 25
Total  number of corpora lutea 360 364 354 345 364
Number of corpora lutea per female Mean 14.4 14.6 14.2 14.4 14.6
SEM 0.5 0.6 0.4 0.4 0.5
Total  number of implantations 317 322 327 319 313
Number of implantations per female Mean 12.7 12.9 13.1 13.3 12.5
SEM 0.5 0.3 0.3 0.4 0.4
Total  number of pre-implantation losses 43 42 27 26 51
Mean  % per group 11.9 11.5 7.6 7.5 14.0
Total  number of post-implantation losses 9 10 13 14 6
Mean  % per group 2.8 3.1 4.0 4.4 1.9
Number of live fetuses per female Mean 12.3 12.5 12.6 12.7 12.3
SEM 0.5 0.3 0.3 0.4 0.4
Number of live fetuses as % of implantations % 97.2 96.9 96.0 95.6 98.1
Total  number of live fetuses 308 312 314 305 307a
Number of males 152 141 162 155 149
Number of females 156 171 152 150 157
Fetal weight (sexes combined) (g) Mean 4.02 4.04 4.02 4.02 4.04
SEM 0.06 0.05 0.04 0.07 0.07
Fetal  weight (males) (g) Mean 4.13 4.16 4.12 4.13 4.14
SEM 0.06 0.06 0.05 0.07 0.06
Fetal  weight (females) (g) Mean 3.90 3.95 3.91 3.91 3.95
a
i
g
a
m
f
(
i
w
T
OSEM 
a One fetus inadvertently not sexed.
nd fetal bodyweight. No female in any group had total litter loss,
.e., completely resorbed litter.
The mean numbers of live fetuses/female were similar in all
roups with no statistically or biologically signiﬁcant differences
mong groups. There were no differences among groups for %
ale fetuses/dam, for mean litter weights/dam, or for individual
etal body weights, with sexes combined or separately, by sex/dam
Table 1).A summary of fetal defects is presented in Table 2, and the
ndividual malformations observed are shown in Table 3. There
ere no statistically signiﬁcant dose-related increases in fetal
able 2
ccurrence of external, visceral and skeletal malformations and variations in the fetuses 
Dose group (mg  Mo/kg bw/day) 0 3 
Total number of fetuses examined 308 312
Total  number of litters examined 25 25
External defects
Number of fetuses examineda 307 312
Number showing malformations 0 1
Number of litters affected 0 1
Number showing variations 0 0
Number of litters affected 0 0
Fresh  visceral body-only defects
Number of fetuses examined 150 151
Number showing malformations 0 0
Number of litters affected 0 0
Number showing variations 7 4
Number of litters affected 5 3
Bouin’s head defects
Number of fetuses examined 150 151
Number showing malformations 0 0
Number of litters affected 0 0
Number showing variations 0 0
Number of litters affected 0 0
Skeletal defects
Number of fetuses examined 158 161
Number showing malformations 1 1
Number of litters affected 1 1
Number showing variations 54 69
Number of litters affected 18 21
a In dose groups 0, 10 and 20 mg  Mo/kg bw/day, 1, 1, and 2 fetuses, respectively were n0.06 0.05 0.04 0.06 0.08
malformations or variations (Table 2). There was  1 externally mal-
formed fetus each at 3 and 40 mg  Mo/kg bw/day; there were 2
fetuses (from 2 litters) at 10 mg  Mo/kg bw/day, and 6 fetuses (from
3 litters) at 20 mg  Mo/kg bw/day with head malformations, and 1,
1, 4, 2 and 1 fetuses (in 1, 1, 4, 2 and 1 litters) with skeletal mal-
formations at 0, 3, 10, 20, and 40 mg  Mo/kg bw/day, respectively.
No treatment related increase in fetal visceral or skeletal variations
was observed. The large numbers of fetuses with skeletal varia-
tions in all groups was anticipated from the historical control rat
data from previous studies in this laboratory in this rat strain. Nasal
sinus, bilateral, enlarged, classiﬁed as a head malformation, was
of rats exposed to sodium molybdate dihydrate.
10 20 40
 314 305 307
 25 24 25
 313 303 307
 0 0 1
 0 0 1
 0 0 0
 0 0 0
 151 152 152
 0 0 0
 0 0 0
 11 2 5
 8 2 4
 151 152 152
 2 6 0
 2 3 0
 0 2 1
 0 1 1
 163 153 155
 4 2 1
 4 2 1
 69 65 64
 22 19 22
ot examined externally but did have visceral or skeletal examination.
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Table  3
Individual incidences of fetal malformations by dose group, dam and fetus of rats exposed to sodium molybdate dihydrate.
Dose group (mg  Mo/kg bw/day) Dam and fetus numbers Findings
0 Dam 18, F 7 Short left rib and cartilage agenesis
3 Dam 29, F 12 Umbilical hernia
Dam 36, F 3 Thoracic vertebral centrum, bipartite ossiﬁcation and bipartite cartilage
10 Dam 51, F 10 Dilated nasal sinus
Dam 60, F 12 Dilated nasal sinus
Dam 63, F 8 Thoracic vertebral centrum, bipartite ossiﬁcation and bipartite cartilage
Dam 67, F 3 Thoracic vertebral centrum, bipartite ossiﬁcation and bipartite cartilage
Dam 68, F 1 Thoracic vertebral centrum, bipartite ossiﬁcation and bipartite cartilage
Dam 64, F 11 Rib 13, right, cartilage agenesis
20 Dam 78, F 1, F 4, F 5 Dilated nasal sinus
Dam 85, F 8, F 10 Dilated nasal sinus
Dam 100, F 10 Dilated nasal sinus
Dam 79, F 5 Thoracic vertebral centrum, bipartite ossiﬁcation and bipartite cartilage
Dam 99, F 9 Rib 13, right, cartilage agenesis
40  Dam 125, F 7 Tail short and curly; rib 7 branched; rib 11 cartilage branched, and thoracic
vertebral centrum, bipartite ossiﬁcation and bipartite cartilage
Table 4
Summary of blood serum and tissue levels of elements, which showed signiﬁcant dose related changes at terminal sacriﬁce of 10 dams per group.
Dose: SMD  ppm in diet (mg  Mo/kg bw/day) 0 100 338 675 1350
0  3 10 20 40
Blood serum levels
Molybdenum Mean (g/ml) 0.024 0.68a 2.43a 4.87a 10.04a
SD 0.003 0.42 0.86 0.98 2.20
Copper Mean (g/ml) 2.02 2.09 2.50a 3.07a 3.98a
SD 0.22 0.34 0.40 0.81 1.12
Placental levels
Molybdenum Mean (g/g dry) 0.75 3.40 15.74a 26.35a 54.51a
SD 1.53 4.02 10.2 9.12 18.06
Copper Mean (g/g dry) 21.3 19.1 29.2 34.2a 50.7a
SD 2.71 5.34 11.8 11.3 21.9
Kidney levels
Molybdenum Mean (g/g dry) 1.51 5.71a 23.0a 38.0a 87.1a
SD 0.10 2.11 9.64 14.7 15.6
Copper Mean (g/g dry) 42.3 44.1 52.6 63.1 118.2a
SD 16.1 19.1 25.4 31.5 33.3
Liver  levels
Molybdenum Mean (g/g dry) 2.47 3.43a 6.14a 9.71a 17.8a
SD 0.14 0.80 1.64 2.20 2.63
Copper Mean (g/g dry) 12.8 13.0 14.7a 17.0 19.5a
SD 0.68 1.94 1.53 4.62 3.46
a Signiﬁcant difference from controls (P < 0.01).
Table 5
Comparison of molybdenum concentrations in placenta and liver reported by Fungwe et al. [22], with current study results.
Fungwe et al. [22]
Dose: mg Mo/L drinking water 0 5 10 50 100
Suggested dose (mg  Mo/kg bw/day)a 0 0.9 1.6 8.3 16.7
Placental levels
Molybdenum Mean (g/g dry) 0.60 1.90 4.32 28.15 45.32
SE  1.9 0.29 0.45 8.40 9.30
Liver  levels
Molybdenum Mean (g/g dry) 2.38 4.50 5.59 10.66 13.15
SE  0.11 0.21 0.37 0.16 0.14
Current study Murray et al. (2014)
Dose: mg Mo/kg bw/day 0 3 10 20 40
Placental levels
Molybdenum Mean (g/g dry) 0.75 3.40 15.74 26.35 54.51
SD  1.53 4.02 10.20 9.12 18.06
Liver  levels
Molybdenum Mean (g/g dry) 2.47 3.43 6.14 9.71 17.83
SD  0.14 0.80 1.64 2.20 2.63
a Suggested dose levels on bodyweight basis by Vyskocil and Viau [4] (see Section 4).
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bserved in 2 fetuses (from different litters) at 10 mg  Mo/kg bw/day
nd in 6 fetuses (from 3 litters) at 20 mg  Mo/kg bw/day; there were
o fetuses with head malformations at 0, 3, or 40 mg  Mo/kg bw/day.
etal skeletal defects were observed in regions of the sternebrae,
ibs, thoracic vertebrae and lumbar vertebrae, with no treatment-
r dose-related pattern of incidences or severities.
There were clearly no dose-related incidences of fetal malfor-
ations in any group. Dilated nasal sinus as described above is an
ncommon fetal ﬁnding, and it was not considered treatment- or
ose-related in this study.
.4. Chemical analyses of serum and tissues
Analysis of the blood serum, placentae, liver and kidneys for
olybdenum and other elements were performed on 10 dams per
roup selected at scheduled necropsy. Of the elements measured
i.e., molybdenum, copper, manganese, iron, cobalt, zinc and sele-
ium), only molybdenum and copper showed clear dose-related
ncreases in levels. A summary of these results for molybdenum and
opper is presented in Table 4. Dose-related increased copper lev-
ls in serum, kidneys, livers and placentae were variously observed
cross all the doses, with statistically signiﬁcant increases in all at
he highest dose.
. Discussion and conclusion
This study is the ﬁrst published developmental toxicity study of
ngested molybdenum in animals performed according to current
esting guidelines (OECD Test Guideline 414) and under GLP con-
itions. Dietary administration of sodium molybdate dihydrate to
regnant rats on GD 6–20 had no signiﬁcant adverse effect on the
eveloping offspring at dose levels up to 40 mg  Mo/kg bw/day (i.e.,
350 ppm of sodium molybdate dihydrate in the diet). No signiﬁ-
ant effects on litter size, resorptions, sex ratio, fetal body weight,
r fetal malformations and variations were observed at any dose
evel tested.
Although no maternal or embryofetal toxicity was  observed in
his study, the highest dose level of 40 mg  Mo/kg bw/day used in the
tudy is approximately 20,000-fold greater than typical equivalent
uman dietary intake of molybdenum (ca. 2 g Mo/kg bw/day, as
eported by Turnlund and Friberg [3]). At the high dose level, the
erum level of molybdenum observed in pregnant rats on GD 20
as 10,040 ng Mo/ml, which is more than 400 times greater than
he control rat values and approximately 10,000-fold higher than
he typical human serum level of 1 ng Mo/ml  [3].
Maternal serum and placental concentrations of copper were
tatistically signiﬁcantly increased compared to controls at doses
f ≥10 and ≥20 mg  Mo/kg bw/day, respectively. However, these
ncreases in copper levels in response to increasing doses of molyb-
enum are considered to represent physiological adaptations, not
 toxic response at these dose levels, since neither symptoms of
aternal toxicity nor developmental toxicity attributable to the
est material were observed. These results are consistent with the
bservation of elevated serum copper in both male and female rats
n a 90-day toxicity study of sodium molybdate dihydrate given in
he diet at dose levels of 17 and 60 mg  Mo/kg bw/day, but not at
 mg  Mo/kg bw/day [8].
The results of the current study are in contrast with those of
he Fungwe et al. [7] study, in which female rats were exposed
o SMD  in drinking water containing 0, 5, 10, 50, or 100 mg  Mo/L
rom weaning at 3 weeks of age until mating at around 11 weeks of
ge, and through pregnancy to sacriﬁce on GD 21. Fungwe et al. [7]
eported increased resorptions and decreased fetal body weight
mong the offspring of pregnant rats given SMD  in the drinking
ater, (estimated doses ≥1.6 mg  Mo/kg bw/day). The magnitude ofoxicology 49 (2014) 202–208 207
the reported decreases in fetal body weights was  substantial, but
not dose related (i.e., 32% and 30% decreases at the estimated doses
of 8.3 and 16.7 mg  Mo/kg bw/day). In contrast, in the present study,
no effects on resorptions or fetal body weights were observed at
dose levels of up to 40 mg  Mo/kg bw/day.
The difference in results between the current study and the
Fungwe et al. [7] study may  relate to differences in route of admin-
istration, duration of exposure, and composition of the diet. These
investigators administered the test material in the drinking water
whereas the current study gave the test material in the diet, which
would be unlikely to result in such a large difference in toxicity.
The duration of exposure and timing of exposure were different.
In the current study, exposure occurred on GD 6–20, and Fungwe
et al. [7] exposed female rats continuously from weaning through
GD 21. Thus, it is theoretically possible, although unlikely, that the
effects observed in Fungwe et al. [7] were due to exposure prior to
implantation.
Interestingly, Fungwe et al. [7] used a semi-puriﬁed diet with a
low molybdenum content of only 0.025 ppm, whereas the present
study used a commercial diet containing 1.8 ppm of molybdenum.
In addition to the very low molybdenum content of the Fungwe
et al. diet, the copper concentration was  lower in the semi-puriﬁed
diet (6.3 ppm) compared to the concentration of copper in the com-
mercial diet (11.6 ppm). A minimum dietary copper concentration
of 8 ppm is recommended for pregnant rats [21]. The lower cop-
per concentration in the semi-puriﬁed diet in the Fungwe et al.
[7] study, together with deﬁciencies of other constituents or nutri-
ents of a semi-puriﬁed diet, may  have contributed to the observed
toxicity in the Fungwe et al. [7] study.
A major deﬁciency in the publication by Fungwe et al. [7] is
that the authors only state the concentrations of molybdenum
added to the drinking water and did not report the dose levels
actually consumed in mg  Mo/kg bw/day. It is not possible to cal-
culate the intakes accurately since neither the water intakes, nor
the body weights of the rats are reported. They quote in their
paper that the molybdenum intake by the pregnant rats from water
per week in the controls, 5, 10, 50 and 100 mg  Mo/L dose groups
were “0, 0.82, 1.65, 7.85 and 17.64 mg/L”. The intake units of mg/L
are clearly incorrect, so we do not know if these ﬁgures should
relate to intake per rat, per 100 g, or per kilogram bodyweight.
Vyskocil and Viau [4] in a review of the paper, made a variety
of assumptions about the probable rat bodyweights and reported
intakes and arrived at estimated intake levels of 0, 0.9, 1.6, 8.3, and
16.7 mg  Mo/kg bw/day in the controls to top dose levels, respec-
tively. In the absence of better published data the suggested intakes
of 0.9 and 1.6 mg  Mo/kg bw/day have been used extensively world-
wide by regulatory authorities in setting the NOAEL and LOAEL
values for molybdenum.
An interesting comparison however can be made between the
tissue levels of molybdenum found in the Fungwe et al. [7] study
and the current study. Data on molybdenum concentrations in
maternal placenta and liver are presented in an earlier publication
based on the same study [22]. Table 5 shows the placental and liver
concentrations of molybdenum found at termination on GD 21 in
the Fungwe study, and the corresponding data from the current
study on GD 20. The similarity of the tissue levels in the two stud-
ies, suggests that the actual intakes in the Fungwe study may  have
been about 3 or more times higher than was  estimated by Vyskocil
and Viau [4].
Previous toxicity studies of molybdate in rodents have reported
that high doses of molybdate produced toxicity, which is associ-
ated with very high blood and tissue levels of copper. The copper,
however, is tightly bound to carrier proteins in the blood and tis-
sues, and it has been suggested that, despite the elevated copper
levels, the toxicity of molybdate was actually related to a reduction
in bioavailable copper [23–26].
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Copper levels in maternal placenta and liver were also mea-
ured in both the current study and by Fungwe et al. [22]. Both
tudies reported that copper levels in these tissues were markedly
ncreased at increasing levels of exposure to molybdenum. How-
ver, the levels of copper in the control groups were markedly
ifferent between the two  studies. The mean copper concentration
n the placentae in the controls was 21.3 g/g dry weight in the cur-
ent study, and 138 g/g dry weight in the Fungwe et al. [22] study.
imilarly, in the liver, the mean copper concentration in the control
roup was 12.8 g/g in the current study, and 101 g/g dry weight
n the Fungwe et al. [22] study. It is surprising that the copper tis-
ue levels were substantially higher in the controls in the Fungwe
t al. [22] study compared to the current study, especially since the
ame strain of rat (Sprague Dawley), but from different sources,
ere used in both studies and that the copper concentration in the
iet was higher in the current study.
In another developmental toxicity study, Sun Su-Ling et al. [9]
eported statistically signiﬁcant changes in the incidence of live
etuses per litter, fetal body measurements and fetal abnormali-
ies in the offspring of pregnant Wistar rats given “molybdenum
cid ammonium salts” by gavage on GD 7–16. However, the spe-
iﬁc chemical identity, purity and source of the test material were
ot provided, and as there are a variety of “molybdenum acid
mmonium salts” it is not clear what substance was  actually tested.
mportantly, the validity of the Sun Su-Ling study is questionable
ecause of clear errors in the published paper, as discussed in the
ntroduction, so this limits the usefulness of the Sun Su-Ling et al.
tudy.
In conclusion, this paper presents the ﬁrst developmental tox-
city study with a molybdenum substance that is compliant with
ECD TG 414 and conducted and reported under GLP principles.
he NOAEL for both maternal toxicity and developmental toxicity
f molybdenum (given as sodium molybdate dihydrate) in the diet
nder the conditions of this study in rats is 40 mg  Mo/kg bw/day,
he highest dose level tested.
The statistically signiﬁcant and dose related alterations
bserved in maternal copper levels in serum and tissues are well
nown after exposure to high levels of molybdenum and are con-
idered as physiological adaptations, not a toxic response at these
ose levels of molybdenum.
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